Skip to content
Review

Abstract 5430: Left Atrial Appendage Occlusion versus Oral Anticoagulation for Anticoagulation Eligible Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Left atrial appendage occlusion (LAAO) is an established non-pharmacological alternative to oral anticoagulants (OACs) in atrial fibrillation (AF) patients at high thromboembolic risk. However, comparative effectiveness across clinical outcomes, particularly across study designs, remains incompletely characterized. Hypothesis: LAAO is non-inferior to OACs for ischemic stroke and systemic thromboembolism (STE) while conferring superior bleeding and mortality outcomes. Methods: A systematic review and meta-analysis was conducted per PRISMA guidelines. Studies comparing LAAO versus OACs in AF patients were included. Primary outcomes were all-cause mortality and major bleeding. Secondary outcomes included cardiac mortality, ischemic stroke, and STE. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated via random-effects models. Heterogeneity was quantified using I 2 and tau 2 . Subgroup analyses by study design (randomized controlled trials [RCTs] versus observational) and leave-one-out sensitivity analyses were performed. Meta-regression assessed the influence of age imbalance between arms. Publication bias was evaluated via contour-enhanced funnel plots. Results: Ten studies comprising 6,094 LAAO and 5,864 OAC patients were analyzed for all-cause mortality; twelve studies (15,684 vs. 15,454) for bleeding; seven for cardiac mortality (4,466 vs. 4,373); nine for ischemic stroke (14,784 vs. 14,560); and nine for STE (13,523 vs. 13,171). LAAO was associated with a non-significant reduction in all-cause mortality (OR 0.73, 95% CI 0.52-1.03; I 2 =83.1%) and a significant reduction in major bleeding (OR 0.71, 95% CI 0.51-0.97; I 2 =86.0%) and cardiac mortality (OR 0.72, 95% CI 0.52-0.99; I 2 =73.2%). Ischemic stroke (OR 0.89, 95% CI 0.70-1.14; I 2 =48.9%) and STE (OR 0.92, 95% CI 0.53-1.60; I 2 =0%) were similar between groups. Subgroup analysis revealed observational studies influenced mortality and bleeding reductions, while RCTs showed neutral effects. Leave-one-out analyses confirmed robustness of all estimates. Meta-regression showed age imbalance did not significantly moderate any outcome (all p>0.05). Conclusions: LAAO significantly reduces major bleeding and cardiac mortality compared to OACs, with comparable ischemic stroke and STE rates. Substantial heterogeneity and design-dependent effect modification underscore the need for adequately powered RCTs to confirm mortality benefits.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.